On Nov 14, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $150 to $185.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $132 to $176.
Goldman Sachs analyst Matthew Sykes maintains with a buy rating, and adjusts the target price from $140 to $160.
Jefferies analyst Tycho Peterson maintains with a buy rating, and adjusts the target price from $142 to $182.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and maintains the target price at $175.
BTIG analyst Mark Massaro maintains with a buy rating, and adjusts the target price from $150 to $185.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The reassessment of estimates for Natera, taking into account the Q3 results along with the revised outlook for 2024 and preliminary commentary on 2025 from the management discussion, supports the view that the stock's significant multiple is well warranted. This is due to several factors that are expected to contribute to both near-term and long-term upside in estimates, positioning the stock as a high-conviction selection.
Natera delivered another robust quarterly performance, according to an analyst. The company is achieving impressive results across various business aspects, such as volume, selling price, margin, and cash burn, with potential for continued enhancement through 2025. The company is considered one of the premier entities within the diagnostics sector.
Natera's Q3 results were exceptionally strong, as evidenced by the continuous improvement in its fundamentals. The company is channeling its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
Natera recorded an impressive quarter with sales, margins, and cash flow that significantly exceeded expectations.
Natera's third quarter revenue and gross margins exceeded estimates, signaling a robust business momentum. This includes a significant 60% year-over-year growth in Signatera clinical volume and noteworthy gains in the women's health sector.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月14日，多家華爾街大行更新了$Natera (NTRA.US)$的評級，目標價介於150美元至185美元。
摩根士丹利分析師Tejas Savant維持買入評級，並將目標價從132美元上調至176美元。
高盛集團分析師Matthew Sykes維持買入評級，並將目標價從140美元上調至160美元。
富瑞集團分析師Tycho Peterson維持買入評級，並將目標價從142美元上調至182美元。
TD Cowen分析師Daniel Brennan維持買入評級，維持目標價175美元。
BTIG分析師Mark Massaro維持買入評級，並將目標價從150美元上調至185美元。
此外，綜合報道，$Natera (NTRA.US)$近期主要分析師觀點如下：
對natera的估計重新評估，考慮到第三季度的結果以及對2024年的修正展望和管理層對2025年的初步評論，支持該股票顯著估值倍數的合理性。這是由於幾個因素，預計將有助於估計的短期和長期上行，使得該股票被視爲高信念的選擇。
根據分析師的說法，natera在另一個強勁的季度表現中取得了成功。這家公司在成交量、銷售價格、利潤率和現金消耗等各個業務方面都取得了令人印象深刻的結果，並有潛力在2025年前持續增強。該公司被認爲是診斷板塊內的頂尖實體之一。
natera的第三季度結果十分強勁，這從其基本面持續改善中可見一斑。該公司正在將其經營現金流重新投入到業務中，這增強了其在銷售、市場營銷、醫療事務和法律事務方面的地位。
natera在本季度實現了令人印象深刻的銷售額、利潤率和現金流，顯著超過預期。
natera第三季度的營業收入和毛利率超過了預期，顯示出強勁的業務勢頭。這包括Signatera臨床成交量同比顯著增長60%以及在女性健康領域的顯著增長。
以下爲今日8位分析師對$Natera (NTRA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
